Products & Alliances
PrEP Biopharm Ltd
hVIVO Innovation Areas
Challenge Study Services
Target & Biomarker Discovery
Aim Rule 26
Press and Media Contact
experimental influenza virus challenge
human monoclonal antibody
hVIVO challenge model
influenza disease model
TCN-032; anti-M2e antibody; influenza viral challenge. influenza rsearch
Scientific Papers: influenza
Scientific paper 112 – Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge
Scientific paper 94 – Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans
Scientific paper – A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness
Scientific paper 93 – Use of a Human Influenza Challenge Model to Assess Person-to-Person Transmission: Proof-of-Concept Study
Scientific paper 103 – Risk Factors Associated with Severe Clinical Outcomes of Pandemic H1N1 Infection
Scientific Paper 97: Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals.
Scientific Paper 78 : Preclinical in vitro activity of QR-435 against influenza A virus as a virucide and in paper masks for prevention of viral transmission.
Scientific Paper 79 : In vivo prophylactic activity of QR-435 against H3N2 influenza virus infection.
Scientific Paper 72 : A throat lozenge containing amyl meta cresol and dichlorobenzyl alcohol has a direct virucidal effect on respiratory syncytial virus, influenza A and SARS-CoV.
Scientific Paper 74 : Scientific lessons from the first influenza pandemic of the 20th century.